Cold Chain Market and Technology Trends

September 06, 2017

The cold chain pharmaceutical market continues to be one garnering specific interest within the logistics space. New therapies such as regenerative therapies and gene therapies as well as a shift toward temperature-managed shipments are currently of significant focus. This is due to many therapeutics being close to commercial launch and the need to be shipped under very exacting temperature conditions. The Drug Supply Chain Security Act (DSCSA), along with FDA 21 CFR GMP and GDP requirements, have also turned a spotlight on the value of these intelligent temperature-controlled materials requiring better and safer transportation solutions. Many companies have turned their focus on three primary areas to respond to these requirements; namely enhanced, reusable packaging, real-time data monitoring, as well as advanced informatics systems to support in transit logistics considerations. In a Contract Pharma article, Mark W. Sawicki, Ph.D., Chief Commercial officer of Cryoport, discusses each of these areas independently in great depth.  Read more >

Questions or comments? We welcome your feedback!

Email Us

Tags: Temperature Controlled Logistics, cold chain shipping, Biopharma Industry News